© Parkinson’s UK, July 2019. Parkinson’s is the operating name of the Parkinson’s Disease Society of the United Kingdom. A charity registered in England and Wales (258197) and in Scotland (SC037554)

Parkinson's UK

About

We are the drug discovery and development arm of Parkinson’s UK, the largest charitable funder of Parkinson's research in Europe.

Our ambition is to invest £22million ($29million) by the end of 2021 raised by Parkinson's UK donors to support projects and companies that are driving towards important new treatments with the potential to transform the lives of people with Parkinson’s.

We select and support projects at the drug discovery, preclinical and early clinical development stages.

Our virtual approach means we can work flexibly and creatively with leading research organisations: clinical and academic institutions, pharmaceutical companies and biotechs worldwide, that can work with us in a results-focused, efficient way to develop and commercialise new treatments for Parkinson’s.

We are looking to create a portfolio of projects that can attract further investment, and we’ll look to partner with companies to take successful projects into the later stages of drug development and trials.

Returns on our investment will include new treatments to stop Parkinson’s and treat its symptoms, and a share in revenue from successful projects will support programmes at Parkinson’s UK.

 
 

News

Please reload

 

Active projects

Novel mitochondrial rescue compounds - University of Sheffield

Screening and in vitro testing programme to identify compounds that rescue mitochondrial function with reduced off-target effects.

Novel mPTP inhibitors - NRG Therapeutics

A preclinical programme to discover and develop a potential drug that could safeguard the dopaminergic cells damaged by Parkinson's and slow down the progression of the condition.

Novel gene transcription modulators - Eurofins Selcia Drug Discovery

A drug discovery and development programme to create molecules that increase the activity of genes  to increase dopamine synthesis and boost the production of neuroprotective proteins.

Phase II trial of cannabidiol for Parkinson's psychosis - King's College London

A 6-week pilot and 12-week double, blind placebo-controlled trial to provide preliminary evidence for the safety and efficacy of cannabidiol (CBD) capsules for the treatment of Parkinson's-related psychosis.

 

Our people

Arthur Roach Ph.D

Director of Research, Parkinson’s UK 

 

Before joining Parkinson's UK Arthur held several academic and industrial positions, most recently as Senior Director, Neurodegenerative Diseases Research at Serono (now Merck). He is also a founder and Head of the SAB of the Swiss-based biotech Chord Therapeutics.

Professor Manfred Auer

Drug Discovery Advisory Panel member

Manfred is currently the SULSA (Scottish Universities Life Sciences Alliance) Professor of Chemical & Translational Biology at the University of Edinburgh. He is one of the most experienced scientists in the field of a assay and screening methodologies and was previously Executive Director of Innovative Screening Technologies at the Novartis Institutes of Biomedical Research.

Professor Paul Whiting

Drug Discovery Advisory Panel member

 

Prior to taking on his current role as the CSO for the Alzheimer’s Research UK UCL Drug Discovery Institute, Paul was Head of Molecular and Cellular Neuroscience at MSD and then Head of Molecular and Cellular Biology at Pfizer Neusentis.

 

Contact

Do you have an idea or a discovery with potential to lead to a new treatment for Parkinson’s? Are you interested in bringing this to the clinic? We can partner with you to develop the most promising projects.

 

Get in touch at virtualbiotech@parkinsons.org.uk

We aim to respond to enquiries, using the details you provide, within 5 working days.

 

Our partners

The University of Sheffield
MedGenesis Therapeutix Inc